(Hill & Knowlton) Boehringer Ingelheim and Lilly today announced Phase III study results for linagliptin, demonstrating improved glycemic control in adults with type 2 diabetes whose blood glucose is not adequately controlled on current therapy.
boehringer ingelheimNew data for linagliptin to be presented at the ADAEurekAlert! - Medicine and Health Mon, 06/27/2011 - 22:00
Lilly, Boehringer collaborate on diabetes drugsHeadlines from the Associated Press Tue, 01/11/2011 - 07:40
INDIANAPOLIS (AP) -- Eli Lilly will pay Boehringer Ingelheim $387.4 million and collaborate with the German drugmaker to develop diabetes drugs with the U.S. pharmaceutical company facing the expiration of some of its key patents.... FDA Panel Finds Tiotropium Safe for COPD PatientsMedPage Today Allergy & Immunology Fri, 11/20/2009 - 11:42
An FDA committee said new data allay concerns about the risk of stroke and cardiovascular events previously associated with tiotropium (Spiriva), drugmaker Boehringer Ingelheim said. |
